Results 1 to 10 of about 151,738 (318)
Identifying potential biomarkers of idiopathic pulmonary fibrosis through machine learning analysis
Idiopathic pulmonary fibrosis (IPF) is the most common and serious type of idiopathic interstitial pneumonia, characterized by chronic, progressive, and low survival rates, while unknown disease etiology.
Zenan Wu+7 more
doaj +2 more sources
Regulatory Immune Cells in Idiopathic Pulmonary Fibrosis: Friends or Foes?
The immune system is receiving increasing attention for interstitial lung diseases, as knowledge on its role in fibrosis development and response to therapies is expanding. Uncontrolled immune responses and unbalanced injury-inflammation-repair processes
Chiel van Geffen+10 more
doaj +2 more sources
Idiopathic pulmonary fibrosis: current diagnosis and treatment [PDF]
Idiopathic pulmonary fibrosis (IPF) is a devastating chronic lung disease without a clear recognizable cause. IPF has been at the forefront of new diagnostic algorithms and treatment developments that led to a shift in patients’ care in the past decade ...
Alexandre Franco Amaral+2 more
doaj +1 more source
Background This American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines and addresses the progression of ...
G. Raghu+40 more
semanticscholar +1 more source
Global incidence and prevalence of idiopathic pulmonary fibrosis
Background Idiopathic pulmonary fibrosis (IPF) is a progressive debilitating lung disease with considerable morbidity. Heterogeneity in epidemiologic studies means the full impact of the disease is unclear.
T. Maher+7 more
semanticscholar +1 more source
IL-18 binding protein can be a prognostic biomarker for idiopathic pulmonary fibrosis.
Idiopathic pulmonary fibrosis is a chronic, fibrosing interstitial pneumonia that presents with various clinical courses and progression ranging from rapid to slow.
Yu Nakanishi+11 more
doaj +1 more source
Pirfenidone and nintedanib are antifibrotic medications approved for idiopathic pulmonary fibrosis treatment by regulatory agencies and available for clinical use worldwide.
F. Amati+6 more
semanticscholar +1 more source
The implications of the recent change in the definition of pulmonary hypertension on epidemiology and outcomes are not known. We sought to determine the percentage of patients with the two most common lung diseases that would be reclassified regarding ...
Steven D. Nathan+7 more
doaj +1 more source
Patients with idiopathic pulmonary fibrosis are screened for circulating autoantibodies as part of the initial interstitial lung disease workup. Management of seropositive idiopathic pulmonary fibrosis is currently considered no different than that of ...
Paraskevi Kirgou+8 more
doaj +1 more source
The Role of DNA Damage and Repair in Idiopathic Pulmonary Fibrosis
The mortality rate of idiopathic pulmonary fibrosis (IPF) increases yearly due to ineffective treatment. Given that the lung is exposed to the external environment, it is likely that oxidative stress, especially the stimulation of DNA, would be of ...
Jiahui Zhu+10 more
doaj +1 more source